Dr. Weintraub's approach emphasizes collaboration and tailored treatment plans, ensuring patients receive the best possible care suited to their unique needs. He specializes in managing patients with a wide range of endocrine conditions, including obesity, diabetes, osteoporosis, and disorders of the thyroid, adrenal, and pituitary.
His particular interest lies in obesity medicine, a dynamic field that offers increasingly effective tools for treating and preventing weight gain, which is often the root cause of many chronic diseases. By working closely with nutritionists, surgeons, and other specialists, he strives to deliver holistic and effective care.
In addition to caring for patients, Dr. Weintraub is passionate about academic medicine, research, and training the next generation of physicians. He co-chairs the pharmacologic management of obesity guideline update through the Endocrine Society and serves on the exam writing committee for the American Board of Obesity Medicine. He is actively involved in clinical research within endocrinology and obesity medicine.
| Fellowship: Endocrinology, Diabetes & Metabolism |
Cornell New York Presbyterian Hospital
Memorial Sloan Kettering Cancer Center
|
| Residency: Internal Medicine |
Thomas Jefferson University Hospital
|
| Medical School |
Rutgers Robert Wood Johnson Medical School
|
| Undergraduate |
University of Pennsylvania
The Wharton School
|
Faculty Director for the New England Journal of Medicine Group's "Advancing Obesity Care" course, collaborating with leading experts to deliver evidence-based approaches for obesity management and GLP-1 therapies.
Learn MoreCo-Chair of the pharmacologic management of obesity guideline update through the Endocrine Society, leading the development of evidence-based recommendations for obesity pharmacotherapy.
Learn MoreServing on the exam writing committee for the American Board of Obesity Medicine, contributing to the certification and education of obesity medicine specialists nationwide.
Learn MoreFeatured expert discussing compounded obesity medications, addressing regulatory considerations, safety, efficacy, and patient access concerns in the evolving landscape of obesity pharmacotherapy.
Listen NowExpert commentary on how the European Association for the Study of Obesity framework reshapes clinical practice by moving beyond BMI to focus on individualized, health-centered approaches.
Watch VideoDiscussing real-world data presented at ObesityWeek on weight regain patterns after GLP-1 discontinuation and implications for long-term obesity management strategies.
Read ArticlePresented real-world evidence on weight regain after GLP-1 discontinuation, highlighting the chronic nature of obesity and the importance of continuous treatment strategies.
View DetailsLecturer for the Columbia Cornell intensive CME program covering evidence-based approaches to obesity etiology, prevention, and treatment. Course emphasizes practical pharmacologic, nutritional, behavioral, and procedural interventions for patient-centered care.
Course InformationRegular speaker on obesity medicine topics including GLP-1 therapies, metabolic complications, and evidence-based treatment approaches.
Connect
NYU Langone Diabetes & Endocrine Associates
222 East 41st Street, 23rd Floor
New York, NY 10017
I actively share research insights, clinical commentary, and updates on obesity medicine and GLP-1 therapies across professional platforms.
Setmelanotide, an MC4R agonist, becomes the first FDA-approved treatment for hypothalamic obesity. Already approved for rare genetic forms of obesity involving the MC4R pathway, setmelanotide demonstrated 18.4% BMI reduction in the TRANSCEND trial of acquired hypothalamic obesity. This represents a valuable therapeutic option for a rare condition where conventional therapies have limited effectiveness.
View ThreadIn this final interview segment with Michael Nauck, MD, we explore practical implementation of oral semaglutide and orforglipron, addressing everyday dosing challenges and missed-dose protocols. We discuss interpreting lean mass shifts and the importance of long-term treatment planning as new GLP-1 therapies enter clinical practice.
Watch InterviewPatients who reduced GLP-1 dosing frequency from weekly to every other week successfully maintained weight loss and metabolic syndrome improvements in this case series. Findings suggest that while substantial GLP-1 level increases may be necessary to induce weight loss, more modest elevations may be sufficient for maintenance.
View ThreadNAION (non-arteritic anterior ischemic optic neuropathy) is a rare cause of blindness reported at higher rates in those taking GLP-1s. The mechanism may involve GLP-1 associated vasodilation leading to optic nerve hypoperfusion and infarction. However, GLP-1RAs also demonstrate neuroprotective properties and reduce ischemic risk. Whether there is true causal risk remains to be determined, as patients taking GLP-1s often have diabetes and hypertension—both independent NAION risk factors.
Read Full PostJoin me for regular insights on obesity medicine, GLP-1 research, and endocrinology
